MOTS-c is a naturally occurring mitochondrial-derived peptide studied largely in cell and animal models. This page describes hypothesized and investigational effects, not an established or FDA-approved treatment.
The short answer
The benefits attributed to MOTS-c — fat loss, insulin sensitivity, endurance, "exercise in a vial" — come from mouse experiments. The human studies that exist are well designed and genuinely informative, and in none of them was MOTS-c administered to anyone. They measured the body's own circulating levels and how those levels move in response to exercise, lipids, and insulin.
That distinction is not pedantry. Observing that a molecule rises with exercise does not establish that adding it reproduces exercise, and that inference is the load-bearing step in nearly every MOTS-c benefit claim.
The mechanism, which is unusually specific
MOTS-c — mitochondrial open reading frame of the 12S rRNA type-c — is a 16-amino-acid peptide encoded inside mitochondrial DNA, described in Cell Metabolism in 2015 (PMID 25738459). Its apparent primary target organ is skeletal muscle. At the cellular level it inhibits the folate cycle and the de novo purine biosynthesis tethered to it, which leads to AMPK activation.
The AMPK claim gets repeated everywhere, usually without the pathway. The pathway is what makes it credible: this is a named, published route, not a hand-wave at "energy."
A 2018 follow-up in the same journal (PMID 29983246) went further, showing MOTS-c translocates to the nucleus under metabolic stress and regulates nuclear gene expression in an AMPK-dependent manner, interacting with stress-responsive transcription factors such as NRF2. A mitochondrially encoded peptide directing nuclear transcription is genuinely novel biology, and it is why academic interest in MOTS-c has been sustained rather than faddish.
What was shown in mice
In the 2015 discovery paper, MOTS-c treatment in mice prevented age-dependent insulin resistance, prevented high-fat-diet-induced insulin resistance, and prevented diet-induced obesity. Those are the results underneath the marketing, and they are real results — in mice, with the peptide administered, with metabolic endpoints measured.
What they establish is that the peptide does something biologically important in a rodent. Mouse metabolic rescue is a common finding that frequently fails to translate; it is a reason to run a human trial, not a substitute for one.
The human data, and what it measured
Two human studies define the clinical literature, and both are observational with respect to the peptide:
- Exercise. A randomized study in the Journal of Applied Physiology (PMID 34351816) assigned 30 participants to endurance exercise, resistance exercise, or control (n=10 each), sampling blood before and at 30 minutes and 3 hours after. Circulating humanin rose significantly after endurance exercise; MOTS-c showed only a trend. Resistance exercise moved neither.
- Lipids and insulin. A Clinical Endocrinology study (PMID 31066084) used intralipid infusion with insulin in women with PCOS and healthy controls. Intralipid significantly raised plasma MOTS-c in both groups, more so in PCOS; subsequent insulin infusion blunted that rise.
Both measured endogenous MOTS-c by ELISA. Neither gave it to a participant. Note also what the exercise study did not find: MOTS-c did not correlate with VO2max, leg strength, or muscle mitochondrial DNA copy number.
The first trial that actually gives it to people
As of 2026 this is changing. A phase 2a randomized, double-blind, placebo-controlled study sponsored by Hudson Biotech (NCT07505745) is recruiting an estimated 120 adults aged 18–65 with prediabetes and a BMI of 27–40, randomizing them to subcutaneous MOTS-c once daily for 12 weeks against matching placebo, with a 4-week safety follow-up. The co-primary outcomes are change in OGTT-derived insulin sensitivity (Matsuda index) at 12 weeks and treatment-emergent adverse events through 16 weeks.
No results have been posted. Until they are, the honest statement is that the first test of whether administering MOTS-c does anything measurable in a human is currently in progress.
Reading the gap
- Established — MOTS-c is a real mitochondrially encoded peptide; it engages AMPK through a defined pathway; it improves metabolic outcomes in mice; its endogenous human levels respond to lipids and insulin.
- Not established — that injecting it into a person produces fat loss, better insulin sensitivity, more endurance, or any effect on aging.
- Unknown — human dosing, bioavailability, half-life of the administered peptide, and safety over any duration.
MOTS-c is not FDA-approved and is not authorized as a treatment for any condition. Reading its literature requires tracking one thing above all: whether the study gave the peptide to a subject or merely measured it.
Sport & Anti-Doping Warning
MOTS-c is a mitochondrial-derived peptide that has drawn attention from anti-doping regulators as a potential metabolic modulator; it was added to the WADA Prohibited List under the section for metabolic and gene modulators.
Because MOTS-c targets core metabolic pathways, anti-doping agencies treat it similarly to other S4 metabolic modulators.